SEC Form 4 · accession 0001479290-18-000054
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phyllis Gardner
Director
Period of report
Mar 16, 2018
Accepted (ET)
Mar 16, 2018 · 8:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 16, 2018 | M | 4,000 | $2.55 | A | 7,000 | D | |
| Common Stock | Mar 16, 2018 | M | 1,333 | $2.55 | A | 8,333 | D | |
| Common StockF1 | Mar 16, 2018 | S | 5,333 | $31.5105 | D | 3,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF2 | $2.55 | Mar 16, 2018 | M | 4,000 | A | — | Apr 29, 2018 | Common Stock | 4,000 | 0 | D |
| Common StockF3 | $2.55 | Mar 16, 2018 | M | 1,333 | A | — | Jul 20, 2020 | Common Stock | 1,333 | 0 | D |
Explanation of responses
- F1The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $31.55. Dr. Gardner undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2The option is fully vested as of January 1, 2012.
- F3The Option is fully vested as of January 1, 2014.